Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biotechnology company with a market capitalization of $906 million, sold 4,308 shares of common stock on July 30, 2025, for approximately $51,743. According to InvestingPro analysis, the company currently shows signs of being undervalued despite facing significant cash burn challenges. The shares were sold at a weighted average price of $12.011, with prices ranging from $11.78 to $12.315. The transaction occurred with the stock trading significantly below its 52-week high of $29.56, amid notable price volatility that has resulted in a 43% decline over the past year.
On the same day, Hansen also acquired a total of 11,815 shares of Nurix Therapeutics common stock through the exercise of restricted stock units. These transactions did not involve any payment.
Following these transactions, Hansen directly owns 69,023 shares of Nurix Therapeutics.
In other recent news, Nurix Therapeutics has been the subject of several analyst updates following its second-quarter financial results. Morgan Stanley (NYSE:MS) adjusted its price target for Nurix to $16.00 from $17.00, citing higher anticipated spending for planned pivotal trials. UBS also lowered its price target to $26.00 from $30.00, attributing the change to increased operational expenses. Despite these adjustments, both firms maintained their respective ratings, with Morgan Stanley keeping an Equalweight rating and UBS a Buy rating. Stifel remains optimistic about Nurix, reiterating its Buy rating and a $35.00 price target, projecting potential peak sales exceeding $4.5 billion for the company’s lead drug candidate. Goldman Sachs initiated coverage on Nurix with a Buy rating and a notably high price target of $182.00, expecting the launch of Crenessity to counterbalance potential challenges to Ingrezza growth. These developments highlight differing perspectives on Nurix’s financial outlook and strategic plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.